Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
British journal of dermatology. - 182, 3 (2020) , 574-592, ISSN: 1365-2133
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
-
Has, Cristina
Liu, Lu
Bolling, Maria C.
Charlesworth, Alexandra V.
El Hachem, Maya
Escámez, Maria Jose
Fuentes Bustos, Maria Ignacia
Büchel, Sarah
Hiremagalore, Ravi
Pohla‐Gubo, Gabrielle
Akker, Peter C. van den
Wertheim-Tysarowska, Katarzyna
Zambruno, Giovanna
- DOI
-
10.1111/bjd.18128
- URN
-
urn:nbn:de:bsz:25-freidok-1662601
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:46 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Has, Cristina
- Liu, Lu
- Bolling, Maria C.
- Charlesworth, Alexandra V.
- El Hachem, Maya
- Escámez, Maria Jose
- Fuentes Bustos, Maria Ignacia
- Büchel, Sarah
- Hiremagalore, Ravi
- Pohla‐Gubo, Gabrielle
- Akker, Peter C. van den
- Wertheim-Tysarowska, Katarzyna
- Zambruno, Giovanna
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Treatment of epidermolysis bullosa and future directions: a review
Molecular therapeutics in development for Epidermolysis bullosa: update 2020
Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa : = Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Junctional epidermolysis bullosa: allelic heterogeneity and mutation stratification for precision medicine
Orale Manifestationen bei Epidermolysis bullosa junktionalis: Genotyp-Phänotyp Korrelationen
A silent COL17A1 variant alters splicing and causes junctional epidermolysis bullosa
Homozygous nonsense mutation and additional deletion of an amino acid in BPAG1e causing mild localized Epidermolysis Bullosa simplex
The position of targeted next-generation sequencing in epidermolysis bullosa diagnosis
Successful multidisciplinary treatment of chronic facial wounds in junctional epidermolysis bullosa
Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study
Treatment of epidermolysis bullosa and future directions: a review
Molecular therapeutics in development for Epidermolysis bullosa: update 2020
Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa : = Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Junctional epidermolysis bullosa: allelic heterogeneity and mutation stratification for precision medicine
Orale Manifestationen bei Epidermolysis bullosa junktionalis: Genotyp-Phänotyp Korrelationen
A silent COL17A1 variant alters splicing and causes junctional epidermolysis bullosa
Homozygous nonsense mutation and additional deletion of an amino acid in BPAG1e causing mild localized Epidermolysis Bullosa simplex
The position of targeted next-generation sequencing in epidermolysis bullosa diagnosis
Successful multidisciplinary treatment of chronic facial wounds in junctional epidermolysis bullosa
Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study
Treatment of epidermolysis bullosa and future directions: a review
Molecular therapeutics in development for Epidermolysis bullosa: update 2020
Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa : = Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Junctional epidermolysis bullosa: allelic heterogeneity and mutation stratification for precision medicine
Orale Manifestationen bei Epidermolysis bullosa junktionalis: Genotyp-Phänotyp Korrelationen
A silent COL17A1 variant alters splicing and causes junctional epidermolysis bullosa
Homozygous nonsense mutation and additional deletion of an amino acid in BPAG1e causing mild localized Epidermolysis Bullosa simplex
The position of targeted next-generation sequencing in epidermolysis bullosa diagnosis
Successful multidisciplinary treatment of chronic facial wounds in junctional epidermolysis bullosa